148 related articles for article (PubMed ID: 2791764)
1. [The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1989 Apr; 22(2):95-8, 126-7. PubMed ID: 2791764
[TBL] [Abstract][Full Text] [Related]
2. [Madopar in the treatment of paralysis agitans: II. TRH activation test, EMG examination and HVA level in cerebrospinal fluid before and after treatment].
Liu DK
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1980 Apr; 13(4):223-6. PubMed ID: 6790255
[No Abstract] [Full Text] [Related]
3. 14C-homovanillic acid in the cerebrospinal fluid of parkinsonian patients after intravenous 14C-L-dopa.
Extein I; Van Woert M; Roth RH; Bowers MB
Biol Psychiatry; 1976 Apr; 11(2):227-32. PubMed ID: 971447
[TBL] [Abstract][Full Text] [Related]
4. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
[TBL] [Abstract][Full Text] [Related]
5. [Results of prolonged treatment of Parkinson's disease with the L-dopa-benserazide combination].
Casacchia M; Barba C; Ruggieri S; Zamponi A; Agnoli A
Riv Neurol; 1974; 44(5):303-30. PubMed ID: 4217465
[No Abstract] [Full Text] [Related]
6. Effect of (-)deprenyl in long-term treatment of Parkinson's disease. A 10-years experience.
Birkmayer W; Birkmayer GD
J Neural Transm Suppl; 1986; 22():219-25. PubMed ID: 3097256
[TBL] [Abstract][Full Text] [Related]
7. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
Poewe WH; Lees AJ; Stern GM
Eur Neurol; 1987; 27 Suppl 1():93-7. PubMed ID: 3322842
[TBL] [Abstract][Full Text] [Related]
8. Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
Marion MH; Stocchi F; Quinn NP; Jenner P; Marsden CD
Adv Neurol; 1987; 45():493-6. PubMed ID: 3548262
[No Abstract] [Full Text] [Related]
9. [Controlled release levodopa-benserazide and changes in efficacy during treatment of Parkinson's disease].
Rondot P; Ziegler M; Aymard N; Holzer J
Rev Neurol (Paris); 1987; 143(11):746-52. PubMed ID: 3324265
[TBL] [Abstract][Full Text] [Related]
10. Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa.
Durso R; Evans JE; Josephs E; Szabo GK; Evans BA; Handler JS; Jennings D; Browne TR
Ann Neurol; 1997 Sep; 42(3):300-4. PubMed ID: 9307250
[TBL] [Abstract][Full Text] [Related]
11. [CB 154 in the treatment of Parkinson's disease. Results in combination with L-dopa and decarboxylase inhibitor].
Meco G; Casacchia M; Zamponi A; Agnoli A
Acta Neurol (Napoli); 1976; 31(4):479-48. PubMed ID: 1037427
[No Abstract] [Full Text] [Related]
12. Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopamine plasma concentrations in fluctuating parkinsonian patients.
Ceballos-Baumann AO; von Kummer R; Eckert W; Weicker H
J Neurol; 1990 Feb; 237(1):24-8. PubMed ID: 2181074
[TBL] [Abstract][Full Text] [Related]
13. [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].
Campanella G; Pennetta R
Acta Neurol (Napoli); 1974; 29(3):252-63. PubMed ID: 4417098
[No Abstract] [Full Text] [Related]
14. A double-blind, cross-over trial with madopar HBS in patients with Parkinson's disease.
De Michele G; Mengano A; Filla A; Trombetta L; Campanella G
Acta Neurol (Napoli); 1989 Dec; 11(6):408-14. PubMed ID: 2694799
[TBL] [Abstract][Full Text] [Related]
15. Tetrahydrobiopterin and Parkinson's disease.
Dissing IC; Güttler F; Pakkenberg H; Lou H; Gerdes AM; Lykkelund C; Rasmussen V
Acta Neurol Scand; 1989 Jun; 79(6):493-9. PubMed ID: 2476906
[TBL] [Abstract][Full Text] [Related]
16. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
[TBL] [Abstract][Full Text] [Related]
17. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
Fernández Pardal MM; Gatto E; Micheli F; Casas Parera I; Diaz S
Medicina (B Aires); 1991; 51(6):561-7. PubMed ID: 7476112
[TBL] [Abstract][Full Text] [Related]
18. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Rinne UK; Marttila R
Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of parkinsonism with L-dopa and peripheral decarboxylase inhibitor].
Dowzenko A; Buksowicz C; Kuran W
Neurol Neurochir Pol; 1975; 9(4):487-93. PubMed ID: 1165836
[TBL] [Abstract][Full Text] [Related]
20. [Development of studies on the treatment of Parkinson syndromes using levodopa. I. Short- and medium-term (2 years) effects of the combination levodopa decarboxylase inhibitor].
Rondot P; Ribadeau Dumas JL; Cardon P
Therapie; 1975; 30(5):653-66. PubMed ID: 769245
[No Abstract] [Full Text] [Related]
[Next] [New Search]
